Cai Xianfu, Ding Chenguang, Li Yang, Zheng Jin, Xue Wujun
Department of Renal Transplantation, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Department of Urology, Mianyang Hospital Affiliated to School of Medicine, University of Electronic Science and Technology of China Mianyang Central Hospital, Mianyang, Sichuan, China.
Front Urol. 2023 Oct 12;3:1239328. doi: 10.3389/fruro.2023.1239328. eCollection 2023.
To utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades. Through this method, we aim to visualize and analyze the research progress in this field and identify the most recent trends and developments.
This research conducted a comprehensive literature review on immunotherapy for castration-resistant prostate cancer. The time frame spanned from January 2003 to December 2022, and the data were extracted from the Web of Science Core Collection database. The application of various software tools, such as CiteSpace, Bibliometrix, and VOSviewer, facilitated the visualization and analysis of the gathered data. These technological utilities illustrated the progression of prominent focus areas within the field.
After excluding irrelevant studies, 373 papers were selected for this study. The findings suggested that the field of immunotherapy for castration-resistant prostate cancer was rapidly developing. The USA was considered to have a significant early entrant advantage in this area and profoundly influenced the field. Similarly, China's National Cancer center demonstrated notable advantages as a recent participant in this research domain. Major research institutions contributing to the field include the University of California, San Francisco; the University of Washington; and the Memorial Sloan Kettering Cancer Research Center. Notably, US authors James L. Gulley, Charles G. Drake, and Lawrence Fong had the largest number of publications in this area. The main research trends for immunotherapy of castration-resistant prostate cancer are membrane antigen expression, checkpoints T-lymphocyte-associated protein 4 (CTLA4) blockade, radium-223, and vaccines, and the refinement of establishing organoid models might fuel castration-resistant prostate cancer immunotherapy research in the ongoing development.
The key trends in immunotherapy research for castration-resistant prostate cancer are membrane antigen expression, CTLA4 blockade, radium-223, and vaccines. Exploring new immune pathways and combining different therapeutic approaches to enhance immune response will be a major trend in the field in the future.
利用文献计量分析方法研究过去二十年发表的关于去势抵抗性前列腺癌免疫治疗的文献。通过这种方法，我们旨在可视化并分析该领域的研究进展，识别最新的趋势和发展。
本研究对去势抵抗性前列腺癌免疫治疗进行了全面的文献综述。时间范围为2003年1月至2022年12月，数据从科学网核心合集数据库中提取。使用CiteSpace、Bibliometrix和VOSviewer等各种软件工具，便于对收集到的数据进行可视化和分析。这些技术工具展示了该领域突出重点领域的发展进程。
排除无关研究后，本研究选取了373篇论文。研究结果表明，去势抵抗性前列腺癌免疫治疗领域正在迅速发展。美国在该领域被认为具有显著的早期进入优势，并对该领域产生了深远影响。同样，中国国家癌症中心作为该研究领域的近期参与者也显示出显著优势。对该领域有贡献的主要研究机构包括加利福尼亚大学旧金山分校、华盛顿大学和纪念斯隆凯特琳癌症研究中心。值得注意的是，美国作者詹姆斯·L·古利、查尔斯·G·德雷克和劳伦斯·方在该领域的出版物数量最多。去势抵抗性前列腺癌免疫治疗的主要研究趋势是膜抗原表达、检查点T淋巴细胞相关蛋白4（CTLA4）阻断、镭-223和疫苗，而建立类器官模型的完善可能会推动去势抵抗性前列腺癌免疫治疗研究在当前发展中不断前进。
去势抵抗性前列腺癌免疫治疗研究的关键趋势是膜抗原表达、CTLA4阻断、镭-223和疫苗。探索新的免疫途径并结合不同的治疗方法以增强免疫反应将是该领域未来的主要趋势。
